Merck KGaA's MS Drug Mavenclad May Defy Doubters

 
• By Kevin Grogan

The German group's oral treatment is late coming to the market but a key opinion leader believes that it will change the way multiple sclerosis is treated.

Man with backpack flies behind a moving train
Not too late: Merck KGaA's new MS drug can still find a place in the market • Source: Shutterstock

More from New Products

More from Scrip